Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Increased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. raised its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 20.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,446 shares of the biotechnology company’s stock after buying an additional 1,240 shares during the period. Envestnet Asset Management Inc.’s holdings in Sarepta Therapeutics were worth $965,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Two Sigma Investments LP boosted its stake in Sarepta Therapeutics by 2,475.1% in the 3rd quarter. Two Sigma Investments LP now owns 789,712 shares of the biotechnology company’s stock worth $87,295,000 after purchasing an additional 759,045 shares during the period. Wellington Management Group LLP boosted its stake in Sarepta Therapeutics by 33.6% in the 1st quarter. Wellington Management Group LLP now owns 2,680,478 shares of the biotechnology company’s stock worth $209,399,000 after purchasing an additional 673,725 shares during the period. Thrivent Financial for Lutherans boosted its stake in Sarepta Therapeutics by 509.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 699,483 shares of the biotechnology company’s stock worth $77,321,000 after purchasing an additional 584,654 shares during the period. Pictet Asset Management SA boosted its stake in Sarepta Therapeutics by 459.7% in the 3rd quarter. Pictet Asset Management SA now owns 667,044 shares of the biotechnology company’s stock worth $73,735,000 after purchasing an additional 547,857 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Sarepta Therapeutics by 124.8% in the 3rd quarter. Renaissance Technologies LLC now owns 884,178 shares of the biotechnology company’s stock worth $97,737,000 after purchasing an additional 490,900 shares during the period. 87.31% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $128.86 on Friday. The company has a market capitalization of $12.00 billion, a PE ratio of -10.15 and a beta of 1.02. Sarepta Therapeutics, Inc. has a one year low of $61.28 and a one year high of $159.89. The company has a debt-to-equity ratio of 1.73, a current ratio of 4.63 and a quick ratio of 4.26. The company’s fifty day moving average price is $132.28 and its 200 day moving average price is $127.35.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last posted its quarterly earnings data on Tuesday, May 2nd. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.46) by $0.49. Sarepta Therapeutics had a negative net margin of 114.30% and a negative return on equity of 128.64%. The company had revenue of $253.50 million for the quarter, compared to the consensus estimate of $241.47 million. During the same quarter in the previous year, the firm posted ($1.20) EPS. The business’s revenue was up 20.2% compared to the same quarter last year. As a group, analysts expect that Sarepta Therapeutics, Inc. will post -10.69 earnings per share for the current year.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of research reports. Citigroup initiated coverage on shares of Sarepta Therapeutics in a research note on Tuesday, April 4th. They set a “buy” rating and a $179.00 target price for the company. Sumitomo Mitsui Financial Group initiated coverage on shares of Sarepta Therapeutics in a research note on Wednesday, April 26th. They set an “outperform” rating and a $185.00 target price for the company. Morgan Stanley decreased their target price on shares of Sarepta Therapeutics from $187.00 to $183.00 in a research note on Wednesday, April 12th. Royal Bank of Canada lifted their target price on shares of Sarepta Therapeutics from $197.00 to $218.00 in a research note on Tuesday, May 16th. Finally, Bank of America lifted their target price on shares of Sarepta Therapeutics from $164.00 to $176.00 in a research note on Monday, May 15th. Two research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $169.65.

Sarepta Therapeutics Profile

(Get Rating)

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.